Report 2017

2017 in brief

 

Financial and sustainability highlights

4%

Organic sales growth

27.9%

EBIT margin

2%

Net profit growth

25.6%

ROIC

76m

Tons of CO2 emissions saved

24%

Renewable energy

1.6

Frequency of occupational accidents

26%

Women in senior management

DKK million 2017 2016 2015 2014 2013
Income statement
Revenue 14,531 14,142 14,002 12,459 11,746
Gross profit 8,413 8,126 8,129 7,149 6,716
EBITDA 5,114 4,960 5,011 4,400 3,639
Operating profit / EBIT 4,047 3,946 3,884 3,384 2,901
Financial items, net (157) (34) (257) (84) (134)
Net profit 3,120 3,050 2,825 2,525 2,201
Balance sheet
Total assets 18,373 18,659 17,791 18,426 16,506
Shareholders' equity 11,267 11,745 11,593 11,280 11,066
Invested capital 12,880 12,584 11,891 10,535 11,871
Net interest-bearing debt 1,642 990 437 (716) 805
Investments and cash flows
Cash flow from operating activities 4,063 3,840 3,339 4,525 2,599
Purchases of property, plant and equipment 1,593 1,076 968 703 762
Net investments excluding acquisitions* 1,665 1,188 1,015 715 783
Free cash flow before net acquisitions and securities 2,398 2,652 2,324 4,229 1,816
Business acquisitions, divestments and purchase of financial assets 3 161 242 14 640
Free cash flow 2,395 2,491 2,082 4,215 1,176
* Excluding The BioAg Alliance impact
2017 2016 2015 2014 2013
Key ratios
Revenue growth, DKK % 3 1 12 6 5
Revenue growth, organic % 4 2 4 7 7
R&D costs (% of revenue) % 13.2 13.2 13.5 14.8 13.0
Gross margin % 57.9 57.5 58.1 57.4 57.2
EBITDA margin % 35.2 35.1 35.8 35.3 31.0
EBIT margin % 27.9 27.9 27.7 27.2 24.7
Effective tax rate % 19.5 21.4 22.0 23.0 20.2
Equity ratio % 61.3 62.9 65.2 61.2 67.0
NIBD/EBITDA 0.3 0.2 0.1 (0.2) 0.2
Return on equity % 27.1 26.1 24.7 22.6 21.3
ROIC including goodwill % 25.6 25.1 25.9 23.1 20.0
WACC after tax % 6.5 6.5 5.3 3.7 4.7
Earnings per share (EPS), diluted DKK 10.49 10.06 9.12 8.02 6.93
Dividend per share (2017 proposed) DKK 4.50 4.00 3.50 3.00 2.50
Key ratios have been prepared in accordance with The Danish Finance Society's "Recommendations & Financial Ratios 2015 Nordic Edition" as well as certain key figures for the Novozymes Group as described in the Glossary.
Environmental and social data
Total number of employees No. 6,245 6,441 6,485 6,454 6,236
Rate of employee turnover % 11.9 10.4 9.1 8.1 7.5
​Frequency of accidents with absence per million working hours 1.6 2.2 2.5 1.7 2.4
Women in senior management % 26 25 24 23 23
Estimated CO2 reductions from customers' application of Novozymes' products* Mill. tons 76 69 60 60 52
* Data for 2013 have been calculated based on life cycle assessment data from 2008.

Sales by geography

North America

Sales increased by 6% organically and by 4% in DKK. Bioenergy posted solid organic growth throughout the year, whereas Agriculture & Feed was negative.

Asia Pacific

Sales increased by 5% organically and by 3% in DKK. All main areas contributed to growth. Technical & Pharma ended slightly down compared with 2016.

Europe, the Middle East & Africa

Sales increased by 4% organically and by 3% in DKK. Food & Beverages and Bioenergy posted good organic growth. Household Care ended flat for the year. Agriculture & Feed and Technical & Pharma declined compared with 2016.

Latin America

Sales declined by 1% organically and by 2% in DKK. The Latin American market continued to be impacted by weak consumer confidence. Bioenergy and Technical & Pharma posted good growth, but was more than offset by a decline in Food & Beverages, Household Care and Agriculture & Feed.

0%

of sales

6 %

organic sales
growth

Sales to the Technical & Pharma industries increased by 13% organically and by 8% in DKK compared with 2015. The strong growth was mainly driven by sales of enzymes for pharmaceutical production, sales of hyaluronic acid and contributions from the royalty agreement with GSK.

0%

of sales

-1 %

organic sales
growth

Sales to the Technical & Pharma industries increased by 13% organically and by 8% in DKK compared with 2015. The strong growth was mainly driven by sales of enzymes for pharmaceutical production, sales of hyaluronic acid and contributions from the royalty agreement with GSK.

0%

of sales

4 %

organic sales
growth

Sales to the Technical & Pharma industries increased by 13% organically and by 8% in DKK compared with 2015. The strong growth was mainly driven by sales of enzymes for pharmaceutical production, sales of hyaluronic acid and contributions from the royalty agreement with GSK.

0%

of sales

5 %

organic sales
growth

Sales to the Technical & Pharma industries increased by 13% organically and by 8% in DKK compared with 2015. The strong growth was mainly driven by sales of enzymes for pharmaceutical production, sales of hyaluronic acid and contributions from the royalty agreement with GSK.

Sales in emerging and developed markets

circle Emerging mar k ets 35 Developed mar k ets 65 % %

Sales by industry

Four out of five of Novozymes’ industries grew in 2017. Food & Beverages and Bioenergy were the main contributors to growth while Agriculture & Feed sales declined as farm economics continue to be under pressure. Novozymes holds an estimated 48% share of the global enzyme market.

% % % % % 28 of sales 18 of sales 15 of sales +1% +9% +11% -3% +2% 32 of sales Household Care Bioenergy Agriculture & Feed 7 of sales Technical & Pharma Food & Beverages Organic sales growth

Economic contribution

In 2017, Novozymes generated value of DKK 14,621 million. 87% of this amount was returned to society. The remaining 13% was reinvested in Novozymes to develop the company, and ensure competitiveness and future value generation for distribution among key stakeholders.

In addition to the 10% returned to capital providers, Novozymes bought back shares worth DKK 2 billion in 2017.

A positive tax contribution
Novozymes’ overall tax strategy and transfer-pricing policy support a positive tax contribution to society and governments in the countries in which Novozymes operates. Novozymes continuously works to fulfill its tax obligations in the countries where it operates. We seek to obtain a competitive tax level in a fair and responsible way, and with full regard to national and international laws and regulations. Besides taxes, our economic contributions include duties, VAT, employee taxes, employee pension and benefit programs, procurement from local vendors and job creation.

In 2017, Novozymes incurred corporate income taxes, and other taxes and duties that came to approximately DKK 1,375 million. In addition, Novozymes collected and withheld tax contributions on dividends and wages totaling approximately DKK 1,375 million. Novozymes’ total tax contribution therefore amounted to approximately DKK 2,750 million, compared with approximately DKK 2,725 million in 2016.



43 used to purchase goods and services from our suppliers % 10 in financial costs and dividends for our capital providers DKK DKK DKK % 9 returned to the community by paying corporation tax, other taxes and duties % 13 reinvested in Novozymes for future value generation % 25 used for employee wages,pensions, etc. % Distributedvalue Generatedvalue Suppliers Sales99 Financial income1 Community Employees Capitalproviders Reinvested inNovozymes DKK 14,621 million % %